Utilisation of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013

Aliment Pharmacol Ther. 2016 Jun;43(11):1124-31. doi: 10.1111/apt.13611. Epub 2016 Apr 6.

Abstract

Background: Surgical fundoplication has been considered to be one of the leading therapeutic modalities for gastro-oesophageal reflux disease (GERD) during the last several decades.

Aim: To determine the trend of surgical fundoplication utilisation in GERD patients during the last decade in the United States.

Methods: Population-based study using a large nationwide database, the Explorys database system, to identify patients diagnosed with GERD and those who underwent surgical fundoplication. Using a quadratic regression model, we determined and compared the trends of surgical fundoplication utilisation annually from 2004 to 2013.

Results: We identified 4 059 060 patients with the diagnosis of GERD, of whom 2343 (0.05%) underwent surgical fundoplication between 2004 and 2013. There was a significant decline in the number of surgical fundoplications performed over the last 5 years from 0.062% in 2009 to 0.047% in 2013 (P < 0.05). Female patients accounted for the majority of those who underwent fundoplication (62.52%). Caucasian patients between the ages of 18 and 65 years were the most likely group to undergo surgical fundoplication (66.28%). The number of overweight patients undergoing surgical fundoplication has been significantly increasing over the last decade (P < 0.05). Importantly, 80% of surgical patients were treated with a proton pump inhibitor (PPI) post surgical fundoplication by 2013 (P < 0.001).

Conclusions: Utilisation of surgical fundoplication in GERD patients has been steadily declining over the past 5 years. The vast majority of patients will resume PPI treatment after surgical fundoplication.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Databases, Factual
  • Female
  • Fundoplication / methods*
  • Gastroesophageal Reflux / surgery*
  • Humans
  • Male
  • Middle Aged
  • Overweight / epidemiology
  • Proton Pump Inhibitors / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • Proton Pump Inhibitors